Home › Trials › NCT06865105

Targeted therapies for treating active psoriatic arthritis in adults

A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis

Phase 2 Interventional AbbVie · NCT06865105

This study is testing if two different treatments for active psoriatic arthritis can help adults feel better and improve their symptoms.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment120 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsrisankizumab, lutikizumab
Locations37 sites (Huntington Beach, California and 36 other locations)
Trial IDNCT06865105 on ClinicalTrials.gov

What this trial studies

This study evaluates the efficacy and safety of targeted therapies for adults with active psoriatic arthritis (PsA). Participants will be randomized into three treatment arms: lutikizumab monotherapy, risankizumab monotherapy, or a combination of both therapies. The study aims to assess changes in disease symptoms and will enroll approximately 120 participants across 40 sites worldwide. Participants will undergo regular visits and procedures throughout the trial.

Who should consider this trial

Good fit: Ideal candidates are adults with a documented diagnosis of active psoriatic arthritis who have not responded adequately to previous targeted therapies.

Not a fit: Patients who have not experienced inadequate responses to prior treatments or have had major surgeries recently may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide new effective treatment options for patients suffering from active psoriatic arthritis.

How similar studies have performed: Other studies have shown promise with targeted therapies for psoriatic arthritis, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participant is willing and able to comply with procedures required in the Master Protocol and substudies.
* Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
* Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline.
* Participant has active plaque PsO and/or a documented history of plaque PsO.
* Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria:

* Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
* Participants with the following chronic or active infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
* Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
* History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

Where this trial is running

Huntington Beach, California and 36 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Psoriatic Arthritis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.